CanSinoBIO Showcases Innovations in Vaccines at World Government Summit 2026

CanSinoBIO's Participation at WGS 2026

CanSino Biologics Inc. (SSE: 688185, HKEX: 06185), a renowned global vaccine manufacturer, has been invited to present its innovative vaccine practices at the World Government Summit (WGS) 2026, which took place from February 3 to 5 in Dubai, UAE. This invitation marks an important second consecutive appearance for CanSinoBIO at the summit, highlighting their commitment to addressing global health issues through innovation and collaboration.

Dr. Xuefeng Yu, CanSinoBIO's Chairman and CEO, took the stage during a panel discussion at the 'New Silk Road Forum' at the summit. He articulated the company's practical experiences in overcoming global public health challenges and stressed the need for enhanced international cooperation to ensure that scientific advancements translate into accessible solutions for diverse populations. "Our mission is to provide innovative, high-quality, and affordable vaccines worldwide," Dr. Yu stated, emphasizing the company’s ongoing commitment to research and development that targets unmet public health needs.

Building on its proprietary innovation platform, CanSinoBIO is adept at responding swiftly to emerging public health demands. By reducing research and development timelines, the company can efficiently deliver solutions across a range of diseases. For instance, its recombinant COVID-19 vaccine, which utilizes an adenovirus type 5 vector, was among the first to gain inclusion on the World Health Organization’s Emergency Use Listing, serving as a crucial component in immunization efforts across several countries.

In 2022, CanSinoBIO also launched the world’s first inhaled COVID-19 vaccine, which has received emergency use approval in China. This revolutionary inhalation technology has now been extended to tuberculosis (TB), with a related vaccine currently undergoing Phase I clinical trials in Indonesia. This showcases how innovative technology can pave new pathways for TB prevention and control while delivering significant value to regions burdened by high disease rates.

CanSinoBIO is also at the forefront of addressing the challenge of global polio eradication with its recombinant polio vaccine (VLP-Polio). Utilizing a novel virus-like particle assembly technology allows the production process to avoid live virus usage, thus minimizing biosafety risks. This vaccine has been recognized by the WHO as a candidate for future polio eradication initiatives, reinforcing the resilience of global immunization systems.

Additionally, advancements in the development of CanSinoBIO's recombinant pneumococcal protein vaccine (PBPV) have yielded promising preliminary results from Phase I clinical trials. This vaccine's straightforward production process not only enhances scalability but also emphasizes quality control, positioning it as a potential supplement to existing pneumococcal vaccines and providing a remedy for sustainable immunization strategies in resource-limited settings.

Over recent years, CanSinoBIO has made substantial strides in its global strategy, forming collaborations in various countries such as Indonesia, Malaysia, Saudi Arabia, and Brazil to localize the impact of its innovations. In Indonesia, for example, the company is facilitating the development of an inhaled tuberculosis vaccine as well as the international launch of the Menhycia® product. In Saudi Arabia and the broader Middle East and North Africa (MENA) region, CanSinoBIO is working on achieving market access and commercialization while exploring joint research, development, and localized production partnerships.

In Malaysia, efforts are concentrated on constructing a vaccine fill-and-finish facility, which is vital for advancing the development of a multivalent mRNA influenza vaccine. These initiatives reflect CanSinoBIO's dedication to contributing to global efforts for influenza prevention and control.

Speaking on the importance of the WGS platform, Ms. Jeanne Wang, Chief Commercial Officer of CanSinoBIO, said, "The WGS serves as a critical platform for advancing international cooperation. We will persist in our international commercial expansion, strengthen our partnerships with governments, local organizations, and international bodies, and explore diverse collaboration models to improve access to innovative vaccines across more nations and regions."

In an increasingly interconnected world, CanSinoBIO's participation emphasizes the significance of collaboration in tackling public health challenges and ensuring that innovative solutions reach those who need them most.